Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 10/20 | 0.56 |
| ▸ | PIM1 | P11309 | 10/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19466739 | 0.90 | RET (0.59) | RETPIM1PIM2 | |
| SCHEMBL19467005 | 0.81 | RET (0.57) | RETPIM1PIM2KDR | |
| SCHEMBL19467254 | 0.81 | RET (0.56) | RETPIM1PIM2 | |
| SCHEMBL19467045 | 0.79 | RET (0.59) | RETPIM1PIM2 | |
| SCHEMBL19467267 | 0.78 | RET (0.58) | RETPIM1PIM2 | |
| SCHEMBL15261920 | 0.77 | PIM1 (0.61) | RETPIM1PIM2KDR | |
| SCHEMBL19237445 | 0.74 | IRAK4 (0.49) | RETPIM1PIM2 | |
| SCHEMBL19466818 | 0.73 | RET (0.61) | RETPIM1PIM2KDR | |
| SCHEMBL4327397 | 0.73 | RET (0.83) | RETPIM1PIM2KDR | |
| SCHEMBL19466752 | 0.72 | RET (0.61) | RETPIM1PIM2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666575-B2 | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections | LEXICON PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-4138844-A1 | 4-(3-(PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIMIDIN-5-YL)PIPERAZINE FOR USE IN THE THE TREATMENT OF COV-229E OR COV-OC43 CORONAVIRUSES INFECTIONS | Lexicon Pharmaceuticals, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-115427045-A | 4- (3- (pyridin-3-yl) pyrazolo [1,5-a ] pyrimidin-5-yl) piperazine for the treatment of COV-229E or COV-OC43 coronavirus infection | 莱西肯医药有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220096481-A1 | PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS | OXFORD FINANCE LLC | 2022-03-31 | — | — | US | disclosed |
| WO-2021216454-A1 | 4-(3-(PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIMIDIN-5-YL)PIPERAZINE FOR USE IN THE THE TREATMENT OF COV-229E OR COV-OC43 CORONAVIRUSES INFECTIONS | LEXICON PHARMACEUTICALS, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-2834243-B1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2822555-B1 | INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN | LEXICON PHARMACEUTICALS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3235499-A2 | INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN | Lexicon Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666575-B2 | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections | IRAK1, SARS1, IRAK2 | RET 755/4885PIM1 154/4885PIM2 333/4885 |
| US-20220096481-A1 | PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS | IRAK1, SARS1, IRAK2 | RET 755/4885PIM1 154/4885PIM2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.